Synopsis
Synopsis
0
KDMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
2. Calipsol
3. Calypsol
4. Ci 581
5. Ci-581
6. Ci581
7. Kalipsol
8. Ketalar
9. Ketamine
10. Ketanest
11. Ketaset
1. 1867-66-9
2. Vetalar
3. Ketaset
4. Ketalar
5. Ketamine Hcl
6. Ketanest
7. Ketolar
8. 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone Hydrochloride
9. Cl 369
10. Cn-52,372-2
11. (+-)-ketamine Hydrochloride
12. Ci-581
13. Ketamine Hydrochloride Ciii
14. Ketamine (as Hydrochloride)
15. O18yuo0i83
16. Calipsol
17. Kalipsol
18. Ketavet
19. (+-)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone Hydrochloride
20. Cl-369
21. Dea No. 7285
22. Cn-523722
23. 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one;hydrochloride
24. Cn-52372-2
25. Ketamine Chloride
26. Ketavet 100
27. Ketavet (veterinary)
28. Ci 581
29. Chebi:650657
30. Einecs 217-484-6
31. Unii-o18yuo0i83
32. Ketalar (tn)
33. Ketamini Hydrochloridum
34. Ketamine Hydrochloride [usan:usp:jan]
35. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, Hydrochloride
36. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, Hydrochloride, (+-)-
37. Ec 217-484-6
38. Chembl1714
39. Schembl26999
40. Dtxsid4040137
41. Ketamine Hydrochloride [mi]
42. 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one Hydrochloride
43. Bcp25943
44. Ketamine Hydrochloride (jp17/usp)
45. Ketamine Hydrochloride [jan]
46. (+/-)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone Hydrochloride
47. Ketamine Hydrochloride [usan]
48. Nsc116131
49. (+/-)-ketamine Hydrochloride, Solid
50. Ketamine Hydrochloride [vandf]
51. Akos005287313
52. Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, Hydrochloride, (+-)-
53. Ketamine Hydrochloride [mart.]
54. Ab02117
55. Ketamine Hydrochloride [who-dd]
56. Ketamine Hydrochloride [who-ip]
57. Nsc-116131
58. Ketamine Hydrochloride [green Book]
59. Db-044614
60. Db-048467
61. Ketamine Hydrochloride [ep Impurity]
62. Ketamine Hydrochloride [orange Book]
63. Ketamine Hydrochloride [ep Monograph]
64. Ketamine Hydrochloride Ciii [usp-rs]
65. Ketamine Hydrochloride [usp Monograph]
66. Ketamini Hydrochloridum [who-ip Latin]
67. C07843
68. D00711
69. 867k669
70. A813079
71. Q-201266
72. Q27105184
73. Ketamine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
74. 2-(2-chlorophenyl)-2-(methylamino)-1-cyclohexanone Hydrochloride
75. Ketamine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
76. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, Hydrochloride (1:1)
77. Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, Hydrochloride, (+/-)-
78. Ketamine (+-)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanonehydrochloride
79. Ketamine Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 274.18 g/mol |
---|---|
Molecular Formula | C13H17Cl2NO |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 2 |
Exact Mass | 273.0687196 g/mol |
Monoisotopic Mass | 273.0687196 g/mol |
Topological Polar Surface Area | 29.1 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 269 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Ketalar |
Drug Label | Ketalar is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injection in concentrat... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Par Sterile Products |
2 of 4 | |
---|---|
Drug Name | Ketamine hydrochloride |
PubMed Health | Ketamine (Injection) |
Drug Label | Ketamine hydrochloride is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injectio... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Hospira; Mylan Institutional; Eurohlth Intl |
3 of 4 | |
---|---|
Drug Name | Ketalar |
Drug Label | Ketalar is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injection in concentrat... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Par Sterile Products |
4 of 4 | |
---|---|
Drug Name | Ketamine hydrochloride |
PubMed Health | Ketamine (Injection) |
Drug Label | Ketamine hydrochloride is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injectio... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Hospira; Mylan Institutional; Eurohlth Intl |
Anesthetics, Dissociative
Intravenous anesthetics that induce a state of sedation, immobility, amnesia, and marked analgesia. Subjects may experience a strong feeling of dissociation from the environment. The condition produced is similar to NEUROLEPTANALGESIA, but is brought about by the administration of a single drug. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) (See all compounds classified as Anesthetics, Dissociative.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Excitatory Amino Acid Antagonists
Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-11-05
Pay. Date : 2019-10-28
DMF Number : 7686
Submission : 1988-09-22
Status : Active
Type : II
Certificate Number : CEP 2005-281 - Rev 02
Issue Date : 2024-03-11
Type : Chemical
Substance Number : 1020
Status : Valid
Registration Number : 218MF10980
Registrant's Address : Raiffeisenstrasse 4, D-77933 Lahr Germany
Initial Date of Registration : 2006-12-01
Latest Date of Registration :
NDC Package Code : 49169-1041
Start Marketing Date : 2024-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF, CA |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
VMF Number : 5368
Submission : 1991-07-15
Status : Inactive
Type : II
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-12-22
Pay. Date : 2022-12-20
DMF Number : 27921
Submission : 2014-01-15
Status : Active
Type : II
Certificate Number : CEP 2016-194 - Rev 01
Issue Date : 2024-05-07
Type : Chemical
Substance Number : 1020
Status : Valid
Date of Issue : 2022-06-29
Valid Till : 2025-07-02
Written Confirmation Number : WC-0218n
Address of the Firm :
NDC Package Code : 61281-8000
Start Marketing Date : 2013-07-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : CA, ASMF, AU |
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
NDC Package Code : 54382-128
Start Marketing Date : 1989-08-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Available Reg Filing : ASMF, CA |
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
NDC Package Code : 54382-114
Start Marketing Date : 1989-02-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF, CA |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37014
Submission : 2022-03-29
Status : Active
Type : II
Certificate Number : CEP 2022-157 - Rev 00
Issue Date : 2024-03-04
Type : Chemical
Substance Number : 1020
Status : Valid
Date of Issue : 2024-02-12
Valid Till : 2027-02-11
Written Confirmation Number : WC-0407
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19082
Submission : 2005-12-16
Status : Active
Type : II
Certificate Number : R1-CEP 1998-125 - Rev 04
Issue Date : 2012-02-09
Type : Chemical
Substance Number : 1020
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5462
Submission : 1984-07-17
Status : Inactive
Type : II
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
GDUFA
DMF Review : Complete
Rev. Date : 2019-11-05
Pay. Date : 2019-10-28
DMF Number : 7686
Submission : 1988-09-22
Status : Active
Type : II
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
GDUFA
DMF Review : Complete
Rev. Date : 2022-12-22
Pay. Date : 2022-12-20
DMF Number : 27921
Submission : 2014-01-15
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-04-06
Pay. Date : 2015-04-16
DMF Number : 29094
Submission : 2015-04-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19082
Submission : 2005-12-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5462
Submission : 1984-07-17
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-06-09
Pay. Date : 2021-04-29
DMF Number : 35385
Submission : 2020-12-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22256
Submission : 2008-11-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37014
Submission : 2022-03-29
Status : Active
Type : II
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
NDC Package Code : 49169-1041
Start Marketing Date : 2024-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
NDC Package Code : 54382-128
Start Marketing Date : 1989-08-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
NDC Package Code : 54382-114
Start Marketing Date : 1989-02-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
NDC Package Code : 61281-8000
Start Marketing Date : 2013-07-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 10920-597
Start Marketing Date : 2013-12-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 73377-250
Start Marketing Date : 2023-09-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 63275-9980
Start Marketing Date : 2010-10-08
End Marketing Date : 2025-12-01
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51552-0697
Start Marketing Date : 2004-09-01
End Marketing Date : 2027-04-30
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 62991-1087
Start Marketing Date : 2009-06-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 38779-1754
Start Marketing Date : 2015-03-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
About the Company : Since its inception in 2003, Seqens has evolved into a global leader in pharmaceutical solutions and specialty ingredients. With a strong focus on customer support, Seqens assists ...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
About the Company : Supriya Lifescience Ltd. specializes in API manufacturing, focusing on therapeutic segments like antihistamines, anti-allergic drugs, vitamins, anaesthetics and anti-asthmatics. Su...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
About the Company : Arevipharma GmbH is a modern manufacturer of active pharmaceutical ingredients and intermediates with more than 140 years of expertise. Our customers are generic and research-based...
About the Company : Arevipharma GmbH is a modern manufacturer of active pharmaceutical ingredients and intermediates with more than 140 years of expertise. Our customers are generic and research-based...
About the Company : Globe Quimica S.A. is a major Brazilian API producer, GMP certificated by ANVISA, manufactures more than 20 different API's such as Antiretrovirals, Anxiolytic, Antidepressant, Ant...
About the Company : Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its ex...
About the Company : SB Pharma GmbH, with its headquarters in Cologne, is a leading company that has set itself the goal of offering pharmaceuticals, medical products and medical devices as well as a b...
About the Company : The word ‘Themis’ means – ‘that which is put in place’ and it is indeed the essence of our company, Themis Medicare, which ‘puts in place’ or integrates people, proce...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
R-107 (ketamine) is an oral NMDA receptor negative allosteric modulator, small molecule drug candidate, which is being evaluated for the treatment of treatment-resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
R-107 Depression Study Results Published in Nature Medicine
Details : R-107 (ketamine) is an oral NMDA receptor negative allosteric modulator, small molecule drug candidate, which is being evaluated for the treatment of treatment-resistant depression.
Product Name : R-107
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 25, 2024
Details:
R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance dosing.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 26, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Douglas Pharmaceuticals Announces Formation of Clinical Advisory Board for Lead Program R-107
Details : R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance ...
Product Name : R-107
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 26, 2023
Details:
R-107 (extended-release oral dose of ketamine) act as a blocks the NMDA receptor and it is investigated for the treatment of treatment resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 15, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial Data Suggests Major Breakthrough in Treatment Resistant Depression
Details : R-107 (extended-release oral dose of ketamine) act as a blocks the NMDA receptor and it is investigated for the treatment of treatment resistant depression.
Product Name : R-107
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 15, 2021
Details:
Ketarx (ketamine) is a NMDA receptor antagonist, being investigated for the management of pain, depression etc.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketarx
Study Phase: Phase II/ Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaTher’s Ketamine Review Extended by FDA with New Goal Set for Aug 2025
Details : Ketarx (ketamine) is a NMDA receptor antagonist, being investigated for the management of pain, depression etc.
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 16, 2025
Details:
ALA-3000, developed by Alar Pharmaceuticals, is the first formulation of ketamine lasting over one week in the blood following single dose and is being developed for Treatment-Resistant Depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: ALA-3000
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alar Doses First Patient in ALA-3000 Study for Treatment-Resistant Depression
Details : ALA-3000, developed by Alar Pharmaceuticals, is the first formulation of ketamine lasting over one week in the blood following single dose and is being developed for Treatment-Resistant Depression.
Product Name : ALA-3000
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 14, 2025
Details:
SP-26 is a novel extended-release ketamine implant which it believes supports SP-26’s potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Musculoskeletal Brand Name: SP-26
Study Phase: PreclinicalProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 30, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
Details : SP-26 is a novel extended-release ketamine implant which it believes supports SP-26’s potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia.
Product Name : SP-26
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 30, 2025
Details:
Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketarx
Study Phase: Phase II/ Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaTher Receives US FDA Approval Goal Date for Ketamine
Details : Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 11, 2025
Details:
Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketamir-2
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 04, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MIRA Starts Phase 1 Trial for Ketamir-2 in Neuropathic Pain
Details : Ketamir-2 (ketamine analog), a novel oral, NMDA receptor inhibitor which is being evaluated for the treatment of patients suffering from neuropathic pain.
Product Name : Ketamir-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2025
Details:
Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketarx
Study Phase: Phase II/ Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaTher Provides Update on FDA New Drug Application for Ketamine
Details : Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 12, 2025
Details:
SP-26 is a ketamine HCl-based injectable dissolvable polymer implant for the treatment of chronic pain and fibromyalgia.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Musculoskeletal Brand Name: SP-26
Study Phase: PreclinicalProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 11, 2025
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silo Pharma Reports Positive SP-26 Study for Chronic Pain & Fibromyalgia
Details : SP-26 is a ketamine HCl-based injectable dissolvable polymer implant for the treatment of chronic pain and fibromyalgia.
Product Name : SP-26
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 11, 2025
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Softgels
Grade : Parenteral, Oral, Topical
Category : Film Formers & Plasticizers, Parenteral, Thickeners and Stabilizers, Topical
Dosage Form : Cream / Lotion / Ointment, Gel, Solution
Grade : Oral, Topical
Category : Emulsifying Agents, Solubilizers, Topical
Application : Emulsifying Agents, Solubilizers, Topical
Excipient Details : Hydrosol 50 is used as a solubilizer and emulsifying agent in oral and topical liquid and semi-solid dosage forms.
Pharmacopoeia Ref : USP/NF
Technical Specs : N/A
Ingredient(s) : Polyoxyl 40 Hydrogenated Castor Oil
Dosage Form : Capsule, Cream / Lotion / Ointment
Grade : Topical and Oral
Category : Film Formers & Plasticizers, Topical
Application : Film Formers & Plasticizers, Topical
Dosage Form : Capsule, Emulsion, Softgel Capsule, Solution, Tablet, Topical Film
Grade : Not Available
Category : Film Formers & Plasticizers, Solubilizers, Topical
Application : Film Formers & Plasticizers, Solubilizers, Topical
Excipient Details : Liquid plasticizer with high ADI, hydrophilic solvent & humectant in emulsions, skin penetration enhancer in topical formulaitons.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Propylene Glycol
05 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-files-abbreviated-new-drug-application-anda-for-preservative-free-iv-ketamine-302474014.html
14 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/14/3081112/0/en/PharmaTher-Unveils-KetaVault-A-First-of-Its-Kind-Portal-to-Accelerate-Ketamine-Research-and-Commercialization.html
14 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/alar-pharmaceuticals-announces-first-patient-dosing-in-a-study-of-ala-3000-extended-release-ketamine-injection-for-treatment-resistant-depression-trd-302454659.html
05 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-files-patent-application-for-nrx-100-its-proprietary-preservative-free-formulation-of-iv-ketamine-302445755.html
30 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/30/3071310/0/en/Silo-Pharma-s-SP-26-Ketamine-Implant-Meets-All-Endpoints-in-Fibromyalgia-Study.html
16 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mira-pharmaceuticals-announces-positive-results-for-ketamir-2-in-diab-1015232
Global Sales Information
Dosage Form : Injection fluid, resolution
Dosage Strength : 10 mg/ml
Price Per Pack (Euro) : 102.41
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Injection fluid, resolution
Dosage Strength : 50 mg/ml
Price Per Pack (Euro) : 109.439
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Injection fluid, resolution
Dosage Strength : 10 mg/ml
Price Per Pack (Euro) : 16.104
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Injection fluid, resolution
Dosage Strength : 50 mg/ml
Price Per Pack (Euro) : 16.819
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Ketamine 100Mg 2Ml 5 Units Paren...
Dosage Strength : 5 vials 2ml 50 mg/ml
Price Per Pack (Euro) : 24.58
Published in :
Country : Italy
RX/OTC/DISCN : Class H
Dosage Form : Solution for injection
Dosage Strength : 50 mg/ml
Price Per Pack (Euro) : 8.54
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Solution for injection
Dosage Strength : 10 mg/ml
Price Per Pack (Euro) : 6.98
Published in :
Country : Norway
RX/OTC/DISCN :
Market Place
Reply
13 Apr 2024
Reply
04 Jan 2024
Reply
08 Dec 2023
Reply
13 Nov 2020
Reply
21 Aug 2019
Reply
18 Jul 2019
Reply
13 Jun 2019
Reply
13 Oct 2018
Reply
09 Oct 2018
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
63
PharmaCompass offers a list of Ketamine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ketamine Hydrochloride manufacturer or Ketamine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ketamine Hydrochloride manufacturer or Ketamine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Ketamine Hydrochloride API Price utilized in the formulation of products. Ketamine Hydrochloride API Price is not always fixed or binding as the Ketamine Hydrochloride Price is obtained through a variety of data sources. The Ketamine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A C13H16ClNO.HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of C13H16ClNO.HCl, including repackagers and relabelers. The FDA regulates C13H16ClNO.HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. C13H16ClNO.HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of C13H16ClNO.HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A C13H16ClNO.HCl supplier is an individual or a company that provides C13H16ClNO.HCl active pharmaceutical ingredient (API) or C13H16ClNO.HCl finished formulations upon request. The C13H16ClNO.HCl suppliers may include C13H16ClNO.HCl API manufacturers, exporters, distributors and traders.
click here to find a list of C13H16ClNO.HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A C13H16ClNO.HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of C13H16ClNO.HCl active pharmaceutical ingredient (API) in detail. Different forms of C13H16ClNO.HCl DMFs exist exist since differing nations have different regulations, such as C13H16ClNO.HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A C13H16ClNO.HCl DMF submitted to regulatory agencies in the US is known as a USDMF. C13H16ClNO.HCl USDMF includes data on C13H16ClNO.HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The C13H16ClNO.HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of C13H16ClNO.HCl suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The C13H16ClNO.HCl Drug Master File in Japan (C13H16ClNO.HCl JDMF) empowers C13H16ClNO.HCl API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the C13H16ClNO.HCl JDMF during the approval evaluation for pharmaceutical products. At the time of C13H16ClNO.HCl JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of C13H16ClNO.HCl suppliers with JDMF on PharmaCompass.
A C13H16ClNO.HCl CEP of the European Pharmacopoeia monograph is often referred to as a C13H16ClNO.HCl Certificate of Suitability (COS). The purpose of a C13H16ClNO.HCl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of C13H16ClNO.HCl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of C13H16ClNO.HCl to their clients by showing that a C13H16ClNO.HCl CEP has been issued for it. The manufacturer submits a C13H16ClNO.HCl CEP (COS) as part of the market authorization procedure, and it takes on the role of a C13H16ClNO.HCl CEP holder for the record. Additionally, the data presented in the C13H16ClNO.HCl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the C13H16ClNO.HCl DMF.
A C13H16ClNO.HCl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. C13H16ClNO.HCl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of C13H16ClNO.HCl suppliers with CEP (COS) on PharmaCompass.
A C13H16ClNO.HCl written confirmation (C13H16ClNO.HCl WC) is an official document issued by a regulatory agency to a C13H16ClNO.HCl manufacturer, verifying that the manufacturing facility of a C13H16ClNO.HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting C13H16ClNO.HCl APIs or C13H16ClNO.HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a C13H16ClNO.HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of C13H16ClNO.HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing C13H16ClNO.HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for C13H16ClNO.HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture C13H16ClNO.HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain C13H16ClNO.HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a C13H16ClNO.HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of C13H16ClNO.HCl suppliers with NDC on PharmaCompass.
C13H16ClNO.HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of C13H16ClNO.HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right C13H16ClNO.HCl GMP manufacturer or C13H16ClNO.HCl GMP API supplier for your needs.
A C13H16ClNO.HCl CoA (Certificate of Analysis) is a formal document that attests to C13H16ClNO.HCl's compliance with C13H16ClNO.HCl specifications and serves as a tool for batch-level quality control.
C13H16ClNO.HCl CoA mostly includes findings from lab analyses of a specific batch. For each C13H16ClNO.HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
C13H16ClNO.HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (C13H16ClNO.HCl EP), C13H16ClNO.HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (C13H16ClNO.HCl USP).